Bifunctional Polypeptide Localizes PD-1 Agonist to Immune Synapse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PD-1 agonist therapies for autoimmune diseases often trigger systemic immune effects and have limited efficacy, necessitating the development of safer and more potent strategies to modulate the PD-1 pathway effectively.
Innovation Solution
A bifunctional binding polypeptide comprising a PD-1 agonist fused to a peptide-MHC binding moiety, such as a T cell receptor (TCR) or TCR-like antibody, is used to localize the agonist to the immune synapse, enhancing specificity and potency by targeting the PD-1 pathway directly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 agonist antibodies are administered systemically to treat autoimmune diseases, then the PD-1 pathway is activated, but systemic immune effects and toxicities occur
Solution Approach 1:
The patent applies local quality by creating a bifunctional polypeptide where one domain targets PD-1 specifically at the immune synapse while the other domain provides antigen-specific targeting. This localized activation at the T cell receptor-antigen complex site ensures PD-1 pathway modulation occurs precisely where needed, avoiding widespread systemic immune suppression while maintaining therapeutic efficacy in autoimmune diseases
2Reliability
If soluble PD-1 agonists are used to trigger PD-1 signaling, then immune activity is modulated, but efficiency is insufficient
Solution Approach 1:
The patent merges two functional domains into a single bifunctional polypeptide: a PD-1 agonist domain and an antigen-specific binding domain (such as a TCR or antibody variable region). This combination ensures that PD-1 signaling is activated efficiently and specifically at the immune synapse where the antigen is presented, dramatically improving signaling efficiency compared to non-specific soluble agonists
3Reliability
If PD-1 agonists are administered to activate the PD-1 pathway, then immune tolerance is promoted, but specificity is limited
Solution Approach 1:
The bifunctional polypeptide achieves high targeting specificity by combining antigen-specific recognition (through TCR or antibody domains) with PD-1 agonist activity. This ensures that immune tolerance is induced specifically in T cells recognizing the target antigen, rather than causing broad immunosuppression, allowing precise control over which immune responses are modulated
Solution Approach 2:
The antigen-specific binding domain acts as an intermediary that directs the PD-1 agonist activity to specific target cells. This mediator ensures that the PD-1 pathway is activated only in T cells that have bound to the specific antigen-MHC complex, providing high specificity for the desired therapeutic effect while avoiding off-target effects
Data Source
AI summary
The present invention provides bifunctional binding polypeptide comprising a pMHC binding moiety and a PD-1 agonist.